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Abstract
The Repressor Element 1 Silencing Transcription factor (REST/NRSF) is a master repressor of neuronal programs in non-
neuronal lineages shown to function as a central regulator of developmental programs and stem cell physiology. Aberrant
REST function has been associated with a number of pathological conditions. In cancer biology, REST has been shown to
play a tumor suppressor activity in epithelial cancers but an oncogenic role in brain childhood malignancies such as
neuroblastoma and medulloblastoma. Here we examined REST expression in human glioblastoma multiforme (GBM)
specimens and its role in GBM cells carrying self-renewal and tumorigenic competence. We found REST to be expressed in
GBM specimens, its presence being particularly enriched in tumor cells in the perivascular compartment. Significantly, REST
is highly expressed in self-renewing tumorigenic-competent GBM cells and its knock down strongly reduces their self-
renewal in vitro and tumor-initiating capacity in vivo and affects levels of miR-124 and its downstream targets. These results
indicate that REST contributes to GBM maintenance by affecting its self-renewing and tumorigenic cellular component and
that, hence, a better understanding of these circuitries in these cells might lead to new exploitable therapeutic targets.
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Introduction
Glioblastoma multiforme (GBM) represents the most frequent
and malignant cerebral neoplasia. Recent research has reported
the presence of a population of cells defined as Glioblastoma Stem
Cells (GSCs) because of their tumorigenic potential and similarities
to the Neural Stem cells (NSCs) (i.e. in vitro growth conditions, self-
renewal, expression of stem cell markers and differentiative,
although aberrant, multipotency) [1,2,3]. These cellular elements
have been suggested to display high chemo- and radio-resistance
features, so that cells escaping surgical removal can regenerate the
tumor despite adjuvant therapies. The elucidation of the molecular
circuitries that control their self-renewal and tumorigenic compe-
tence can therefore likely foster the development of new targeted
therapeutic approaches.
The RE1-silencing transcription factor (REST) [also known as
neuron-restrictive silencer factor (NRSF)] has been characterized
as a master repressor of neuronal programmes in non-neuronal
tissues [4,5,6,7]. REST binds to a highly conserved 21–23 bp
DNA sequence called RE1 (repressor element 1) located in
many neuronal genes and silences their transcription by
recruiting specific co-repressors multicomplexes [8]. REST
targets include a large number of genes that encode for
neuron-specific proteins. Genome- and transcriptome-wide
analyses focused on the RE-1 sequence have revealed a REST-
regulated network with over 1000 genes and several microRNAs
in humans [9,10,11]. REST has been shown to coordinate
neural induction and neuronal differentiation programs during
both in vivo and in vitro neurodevelopment [12,13,14,15]. Of
note interfering with REST levels leads to altered NSCs
differentiation and aberrant REST function has been associated
with neurological disorders [16,17,18,19]. In human epithelial
cells REST has been described as a potent suppressor of
malignant transformation [20] and its deregulation has been
associated with several non-neural tumors including breast and
small cell lung cancers [21,22]. However, oncogenic roles for
REST have been observed in neuroblastoma [23] and
medulloblastoma [24]. To date, although a certain level of
REST amplification was reported in 36% of GBM specimens
[25] and a study indicated expression of REST in GBM cells
[26], whether REST levels and functions play critical roles in
GBM yet represents a critical issue. Here, we report that REST
is expressed in human GBM specimens and that its down-
regulation strongly impairs self-renewal and tumor-initiating
capacity of GBM cells. These results indicate that REST plays
critical functions in human GBM.
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REST Expression is Elevated in Human GBM
To investigate if REST plays a functional role in GBM, we first
evaluated, by quantitative real-time PCR assay, REST expression
levels in 15 tumor specimens collected from independent primary
GBMs patients. In all samples, REST is expressed and
upregulated from two- to five-fold as compared to control mRNA
obtained from pooled adult normal cerebral cortex tissues
(Figure 1A). Interrogation of the National Cancer Institute’s
Repository for Molecular Brain Neoplasia Data (REMBRANDT)
[27] also indicated a 45% average increase of REST expression in
gliomas compared to control (non-tumor) tissue (Figure S1A). As
elevated levels of mRNA may reflect an increase in gene copy
number, we sought to determine whether genomic changes in
REST occurred in glioma patients. Copy number REMBRANDT
analysis for REST indicated a 3-fold or greater amplification of the
4q12 chromosomal region which correlated with a slightly worse
survival, while a deletion is strongly associated to a better survival
(Figure S1B). To confirm the high REST expression in GBM
tissues and to extend the analysis to protein level and REST
cellular distribution, we performed an immunohistochemistry
screening on 96 paraffin-embedded primary human brain tumor
surgical biopsy specimens (Table 1). A detailed mapping of REST
positive cells in diverse brain tumors has not been reported in the
literature. In the control specimens, REST immunoreactivity was
detected in the cytoplasm of selected neurons in the cerebral
cortex and in dentate gyrus of hippocampus (Figure 1B). Glial cells
diffusely showed a nuclear staining (Figure 1C). In neuroepithelial
and non-neuronal tumors, REST immunoreactivity variably
marked different cell populations, although with variable degrees
both in terms of intensity and percentage of positive cells (Table 1;
Figure S2A-F). In general, gliomas exhibited a nuclear staining
which intensity increased with anaplasia (Figure 1D and E; Figure
S2). REST was detected in all GBM specimens (the number of
positive tumor cells differed between individual cases, ranging
from 10 to 75%; Table 1) in phenotypic areas characterized by
high cell density, small and hyperchromatic nuclei (Figure 1F and
G). Immunoreactivity appeared as a strong nuclear-restricted
staining, particularly intense in the perivascular districts
(Figure 1H), areas known to be characterized by the highest
malignancy and which also show high expression of Sox2
(Figure 1I) and nestin (not shown). Interrogation of the Human
Protein ATLAS database (www.proteinatlas.org/) confirmed the
same REST immunoreactive signal and cellular distribution,
obtained with different antibodies with respect to the one here
employed.
Elevated REST Expression is Maintained in Human
Tumorigenic-competent GBM Cells
Since previous studies suggested that the perivascular region is
enriched for cellular elements defined as Glioblastoma Stem Cells
(GSCs) because of their tumorigenic potential and some similar-
ities to the Neural Stem cells (NSCs) [28], we assayed REST
expression levels in self-renewing and tumorigenic competent cell
populations that we have established from primary GBMs.
Quantitative real-time PCR assay confirmed high level of REST
mRNA expression, comparable to those observed in normal
human fetal brain-derived NSCs and consistently higher com-
pared to adult normal (non-pathological) brain tissue, in all the
analyzed GBM-derived cells cultured in mitogen-supplemented
Serum Free (SFM) conditions typically employed for growing
NSCs (Figure 2A), both as adherent monolayer [29] (here named
‘‘GB cells’’; for a characterization of GB cells see Figures S3 and
S4) or as neurospheres. Immunocytochemistry confirmed the
presence of REST nuclear signal in GB cells (Figure 2B).
Noteworthy, a strong dotted staining could be observed in the
nuclei, likely corresponding to nuclear foci, where co-expression of
REST and telomere repeat factor 2 (TRF-2) has been previously
reported [26].
REST Knockdown Reduces Self-renewal Potential of
Human Tumorigenic-competent GBM Cells and Induces
Neuronal Differentiation and Cell Death Programs
To uncover the functional role for REST in tumorigenic-
competent GBM-derived cells, we assessed its ability to control
self-renewal and neuronal differentiation, both programs known to
be regulated by REST in normal NSCs [12,13,14,15,30,31,32].
REST targeting in GB cells by using lentiviral transduced short
hairpin RNAs (shREST), resulted in a 75% silencing rate at the
mRNA level (Figure S5A and B) and approx. 90% at the protein
level (Figure S5C and D). In these cultures, REST targeting
induced a marked morphological change in the cells, exhibiting
a flatter appearance with respect to mock infected cells (CTRL)
and cultures receiving non-targeting shRNA (NT shRNA)
(Figure 3A). Furthermore, REST downregulation impaired self-
renewal capacity, resulting in the inability to stably propagate
shREST GB cells (Figure 3B and Figure S6). Similar effects were
observed when performing a neurosphere assay on malignant
GBM cells growing in suspension. In this assay, shREST cultures
exhibited a decrease both in spheres’ number and size with respect
to CTRL and NT shRNA cultures (Figure S7A-C). Antigenic
analysis of the shREST cultures indicated a reduction of the
number of nestin positive cells (CTRL: 90.9% 612.4; NT shRNA:
91.9% 69.7; shREST: 29.1% 67.3; P,0.001) (Figure 3C and D).
Of note, although the number of Olig2 positive cells did not
substantially vary upon REST knockdown (P,0.05), we did
observe a significant effect on the subcellular localization of Olig2
in nestin negative cells, where it exhibited a diffuse cytoplasmic
and nuclear distribution, different from the typical nuclear-
restricted expression (see arrows in Figure 3C). Concurrently,
REST targeting induced a dramatic increase in the number of b3-
tubulin positive cells (CTRL: 5.7% 60.3; NT shRNA: 4.1% 60.4;
shREST: 76.0% 69.5; P,0.001) (Figure 3C and D), as expected
since it is among the REST-regulated genes, accompanied by
a four-fold and ten-fold reduction of GFAP positive and phospho-
H3 positive cells, respectively (P,0.001) (Figure 3C and D).
Together these results indicated that REST knockdown induces
cell-cycle arrest, impairs self-renewal and instructs the cells toward
a neuronal fate. Similar results were obtained in three independent
GB cell lines and in normal human NSCs and were further
strengthened in GB cell cultures exposed to differentiating
conditions (Figure S8). We also found that REST de-repression
in GB cells stimulated an apoptotic program as shown by
increased active-Caspase 3 immunoreactivity in REST-targeted
cultures both in self-renewal (Figure 3C and D) and in
differentiating conditions (Figure S8). To test the specificity of
REST targeting, we transfected GB cells with REST-specific
(siREST) or non-targeting (NT siRNA) siRNAs (Figure S9A and
B). siREST transfection caused a relaxation of REST transcrip-
tional repression activity on BDNF and SNAP25, two well-
characterized REST-controlled genes (Figure S9C). Furthermore,
siREST transfection resulted in increased apoptosis, as determined
with Annexin V staining (CTRL: 36.3% 63.5; NT siRNA: 38.4%
64.7; siREST: 65.1% 66.3; P,0.001) (Figure 3E) and lumino-
metric assay for Caspases 3/7 activation (P,0.001) (Figure 3F).
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Tumorigenic-competent GBM Cells Xenograft and
Impairs in vivo Tumor Growth of Established Xenograft
Tumors
According to the in vitro requirements for REST in the survival
and self-renewal capacity of GB cells demonstrated so far, it would
be expected that delivery of REST-specific shRNA could affect
their tumorigenic capability in vivo. To address this issue, GB cells
were transduced with shREST or NT shRNA followed by a 3 days
of puromycin selection to completely eliminate non transduced
cells and afterwards cells were transplanted into the brains of
immunocompromised SCID mice. Animals bearing shREST GB
cells displayed no tumor formation and complete survival when
compared to the ones receiving NT shRNA GB cells or not
transduced GB cells (CTRL), up to 6 months post-transplantation,
the latest time point we have examined (P,0.001) (Figure 4A).
Histological analyses confirmed that NT shRNA transduced GB
cells developed into tumors which invaded the brains, whereas no
tumor developed in the brains receiving shREST transduced GB
cells (Figure S10). To further confirm this result, mock transfected
cells (CTRL) or NT siRNA or siREST transfected GB cells were
heterotopically injected in immunocompromised SCID mice and
tumor formation and growth was monitored. Within 12 days post-
injection CTRL and NT siRNA injected animals developed tumor
masses whose volume progressively increased with time, while in
the same period no tumors could be detected in animals injected
with REST targeted cells up to 50 days (P,0.001) (Figure 4B).
However, these animals showed a delayed formation of tumors (80
days after the injection), likely because of the presence of
unsuccessfully targeted cells. We conclude that targeting REST
in GB cells is sufficient to impair their in vivo tumorigenic
competence.
This was further verified by directly interfering with REST
activity in vivo. For this purpose, NT shRNA or shREST lentiviral
particles were directly delivered in GB-derived heterotopic tumors.
Prior injection of lentiviral particles carrying eGFP reporter was
used to determine the feasibility of the intratumoral delivery
procedure and to set up the appropriate lentiviral injection dose
(Figure S11A). Two intratumoral injections in seven days interval
were performed in order to target a wider tumor area. In all
experiments, animals receiving NT shRNA treatments exhibited
the typical progressive growth of the tumor masses, whereas mice
receiving shREST particles displayed a partial but significant
reduction of the tumor growth rate, already after 10 days (day 50
after cell injection in Figure 4C) from the first lentiviral particles
injection (P,0.001). Analysis of these tumor samples indicated the
presence of areas exhibiting b3-tubulin and active Caspase 3
immunoreactivities, likely corresponding to the sites of shREST
lentiviral particles injection (Figure S11B). Collectively, these data
indicate that direct REST inhibition in vivo can interfere with
growth of malignant GBM cell-derived xenograft tumors by
activation of apoptosis and neuronal differentiation programs.
REST Controls SCP1 and PTPN12 Phosphatases
Expression Levels in Human Tumorigenic-competent
GBM Cells by Modulating miR-124 Levels
Taken together, our study suggests that self-renewal, growth and
survival of GBM-derived GB cells are critically dependent on
REST activity and that inhibition of REST-regulated pathways
might disclose potentially exploitable strategies towards GBM
treatment in human. Nevertheless, our study reports the presence
of REST positive cells in diverse gliomas and defines a role for
REST as a positive regulator of self-renewal in tumorigenic-
competent GBM-derived cells. Noteworthy, analyses of REST
transcript in relation to the TCGA subgroups does not provide any
hint about REST mRNA levels in relation to the TCGA
subgroups. This is in agreement with very recent findings
reporting that analysis of REST mRNA levels cannot be used to
Figure 1. REST expression is elevated in human GBM. (A) Quantitative RT-PCR analysis of REST mRNA level, relative to GAPDH, in human
primary GBM specimens compared to pooled non pathologic human cerebral cortex tissues (CTX). Results are relative to three independent
experiments. Data are means 6 s.d. and were analyzed with Student’s t-test. (B-I) Representative images of immunohistochemical staining of REST in
human non pathologic brain tissue and glioma specimens. (B) Neurons of pontine nuclei with nuclear and cytoplasmic staining. DAB, 4006. (C) Glial
nuclei in the hemispheric white matter. DAB, 4006. (D) Diffuse astrocitoma: few nuclei are weakly positive. DAB, 2006. (E) GBM: all the nuclei in
peculiar proliferating areas are intensely positive. DAB, 4006. (F) GBM: nuclei of hypercellular areas with high vessel density are intensely positive.
DAB, 1006. (G) Inset of (f). DAB, 4006. (H and I) GBM: intense nuclear staining in perivascular cell cuffings for REST and Sox2 respectively (vascular
tissue is revealed by CD-31 immunoreactivity). Double staining (REST-CD31, Sox2-CD31), 4006.
doi:10.1371/journal.pone.0038486.g001
Table 1. Intensity and distribution of REST expression and demographic data (male:female ratio, mean age, age range) of the
tumor specimens analysed in this study.
Tumor diagnosis Total cases Male: female ratio
Mean age at
diagnosis (years)
Age range
(years)
REST
+ve
Cells (%) Intensity
Glioblastoma Multiforme 60 37:23 62 23–81 10–75% ++/+++
Diffuse astrocytoma 3 2:1 47 38–56 10–20% +
Anaplastic astrocytoma 6 4:6 66 51–75 30–50% +
Pilocytic astrocytoma 6 2:4 45 19–65 100% ++
Oligodendroglioma 10 5:5 55 45–67 10–20% +
Anaplastic oligodendroglioma 7 4:3 55 31–80 30–40% +/++
Medulloblastoma 3 2:1 35 32–39 10–50% +/++
Central neurocytoma 1 Female 22 / positive +
Normal nervous tissue 2 1:1 46 43–49 / /
doi:10.1371/journal.pone.0038486.t001
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mRNA level, relative to GAPDH, in different human GB lines grown as monolayer cultures or floating neurospheres compared to pooled non
pathologic human cerebral cortex tissues (CTX) and to normal fetal-derived human Neural Stem Cells (NSCs). Data were analyzed with Student’s t-
test. Results are relative to three independent experiments. Data are means 6 s.d. (B) REST immunofluorescent staining of a representative GB cell
line (GB7 cells). All the cells show diffuse REST nuclear signal. Signal specificity is demonstrated by competition with a specific REST blocking peptide
(BP; bottom line).
doi:10.1371/journal.pone.0038486.g002
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PLoS ONE | www.plosone.org 5 June 2012 | Volume 7 | Issue 6 | e38486Figure 3. REST knockdown reduces self-renewal potential of human tumorigenic-competent GBM cells and induces neuronal
differentiation and cell death programs. (A) Representative live image of GB7 cells maintained in self-renewal conditions, 4 and 7 days after
REST shRNA knockdown (shREST) and relative controls (CTRL: mock infected cells; NT shRNA: non targeting shRNA). REST knockdown causes
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PLoS ONE | www.plosone.org 6 June 2012 | Volume 7 | Issue 6 | e38486reduction of proliferation and dramatic morphological changes, with appearance of a large proportion of flat and differentiated cells (arrows). (B)
Colorimetric MTT-based cell viability assay performed on controls and shREST GB cell cultures. (C) Immunofluorescent analyses of controls and shREST
self-renewing GB7 cells (7 days post infection). There is an evident reduction in the expression of neural progenitor (Nestin) and proliferation (P-
HisH3) markers in shREST cells with respect to controls, with a parallel increase of neuronal differentiation (b3-tubulin) and apoptosis (Activated
Caspase 3) markers. (D) Relative quantification of the numbers of immunoreactive cells in (C). CTRL: light gray bars; NT shRNA: dark gray bars; shREST:
black bars. At least 700 cells per group were scored. (E) Detection of apoptosis on REST depleted GB cells. Seven days after siRNA transfection, the
percentages of apoptotic GB7 cells in the cultures were analysed by FACS Annexin V–PE assay. (F) Luminometric detection of apoptosis on REST
depleted GB cells. 48 and 72 hours after siRNA transfection, apoptosis in controls and siREST treated GB7 cells was analysed by Caspase-Glo 3/7 Assay.
Data were analyzed by one-way ANOVA comparison of the controls groups and of the REST knockdown cultures. Results shown are relative to three
independent experiments. Data are means 6 s.d. ns not significant, *P,0.001, **P,0.05.
doi:10.1371/journal.pone.0038486.g003
Figure 4. REST knockdown abolishes tumor formation by human tumorigenic-competent GBM cells xenograft and impairs in vivo
tumor growth of established xenograft tumors. (A) Kaplan-Meier survival curve of SCID mice transplanted intracranially (n=4per each group)
with GB7 cells transduced with NT shRNA or shREST lentiviruses (prior to transplantation, cultures were subjected to three days of puromycin
selection in order to eliminate non-infected cells). (B) REST siRNA targeting suppresses tumor formation of heterotopically GSC xenografts. Two days
after GB7 cells transfection with non targeting (NT siRNA) and REST (siREST) siRNA were bilaterally injected subcutaneously in SCID mice (n=5
injected flanks per each group). An equal number of non-transfected cells were used as control (mock transfected cells: CTRL). Tumors formation was
manifest after 12 days in the CTRL and NT siRNA groups while there was no evidence of tumor formation in siREST group. (C) In vivo intra-tumoral
injection of REST shRNA impairs growth of heterotopic established tumors. GB7 cells were subcutaneously implanted into mice flanks and once
tumors were established, lentiviral particles carrying either non-targeting shRNA (NT shRNA; n=4) or shRNA directed against REST (shREST; n=4)
were delivered to tumor site through direct injection (two injections with 7 days interval; arrows in the graph). Tumor growth was unaffected in NT
shRNA control group while a marked slowdown of tumor growth is evident in shREST group. Data are means 6 s.d. ns not significant, *P,0.001,
**P,0.01.
doi:10.1371/journal.pone.0038486.g004
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relation between REST mRNA and protein levels [33]. Analysis of
protein levels and distribution is extremely important in the case of
REST as its post-translational modifications have been shown to
regulate cell maintenance [30,31]. Interfering with mechanisms
regulating REST post-translational modifications have been
shown to affect NSCs differentiation and cellular transformation
in non-neural epithelial cells [20,31]. In particular, the net balance
between the b-TrCP-mediated ubiquitylation and the HAUSP-
mediated deubiquitylation has been shown to control REST
protein levels and determine cellular fate in mouse and human
NSCs [30]. Of note, it has been reported that the association of
TRF-2 with REST also prevents the ubiquitin proteasome-
mediated degradation of REST [34,35]. Consistently, our in-
terrogation of the Human Protein ATLAS database indicates
strong expression of HAUSP and TRF2 and, conversely, reduced
level of expression of b-TrCP in malignant glioma specimens with
respect to non-pathologic brain tissue (not shown).
On the whole, our results support the hypothesis that in neural
tissue, differently from non-neural compartments, REST favours
the self-renewal and tumorigenic competence of tumor cells. The
fact that REST can be either permissive or inhibitory for tumor
formation, depending on tumor’s types, points to a context-specific
modulation of REST-controlled pathways. miRNAs are crucial
organizers of tissue-specificity [36] and REST has been shown to
control the expression of different miRNAs [11,37]. Among them,
miR-124 represents the most differentially expressed miRNA
between GBM and normal brain being poorly expressed in GBM
[38,39]. Of note, miR-124 levels directly correlated with patients’
survival [39]. miR-124 expression increases during NSC differen-
tiation [40], and over-expression of miR-124 in putative GBM-
derived stem cells has been shown to induce a dramatic increase in
neuronal differentiation markers accompanied by reduced self-
renewal and tumorigenicity [38]. We thus assayed miR-124
expression levels in normal and REST-depleted GB cells.
Quantitative real-time PCR assay showed low miR-124 levels in
CTRL and NT shRNA cultures, but a tenfold increase in shREST
cultures (Figure 5A). We also found that the increase of miR-124
levels in REST-depleted GB cells resulted in a substantial
reduction of SCP-1 and PTPN12 levels (Figure 5B), two
phosphatases whose expression has been previously demonstrated
to be controlled by a REST-miR-124 circuitry [41,42]. Impor-
tantly, SCP-1 and PTPN12 play crucial roles in suppression of
differentiative and oncogenic programs [42], respectively. These
results indicated the conservation of REST inhibitory effect on
miR-124 in GBM in human and we can speculate that one
mechanism by which REST sustains self-renewal and tumorigenic
competence of isolated GB cells might be through the repression of
miR-124 expression (and deregulation of miR-124 targets)
(Figure 6).
Our data define REST as an important mediator of GBM
biology by demonstrating that REST is involved in GBM
maintenance through regulation of the self-renewal, survival and
differentiation of malignant GBM cells, and suggest that REST-
regulated molecular circuitries may potentially turn into sensible
targets for therapeutical intervention in GBM.
Materials and Methods
Ethics Statement
All the human tissues used in this study were collected only
when necessary as part of treatment. Only samples in excess of
what was needed for pathological assessment were used for
research. Written informed consent to utilize excess tissue for
research was obtained from each patient, and de-identified tissues,
to protect anonymity, were used.
GB cell lines described in this manuscript were generated from
tumor samples obtained during planned neurosurgical procedures
for resection of newly diagnosed glioma at the Neurosurgical unit
of the IRCCS Policlinico S. Matteo, Pavia, Italy. Surgery was
performed according to the recommendation of the institutional
review boards and in full agreement with the principles of the
Declaration of Helsinki. For the use of the tumor samples for the
generation of GB cell lines a written informed consent was
obtained from each patient and the study approved by The Ethics
Committees of the IRCCS Policlinico S. Matteo, Pavia, Italy.
Cancer cell lines G144, G166 and G179, as well as the human NS
(hNS; CB 541 and CB 192 cell lines) cells, were donated by Prof.
Austin Smith (University of Cambridge, UK) who reported their
generation and characterization elsewhere [29,43]. GBM neuro-
sphere line (NSGBnR1) were donated to our lab by Dr. Gaetano
Finocchiaro (Istituto Neurologico C. Besta, Italy); these cells have
been previously generated and described by the lab of Dr.
Gaetano Finocchiaro [44]. Tumor specimens used for the
immunohistochemistry analyses were collected in Italy at the
Center of Policlinico di Monza Foundation and approval was
obtained from the Institutional Ethics Board and in in full
agreement with the principles of the Declaration of Helsinki.
All animal procedures were carried out in strict accordance with
the legislation and guidelines for animal care and handling in Italy
(DL116 92) approved by the Italian Ministry of Health, and those
from the European Union (2003/65/CE from the European
Parliament and Council July 2003). The protocols were approved
by the Bioethical Committee of the University of Milan and by the
Committee on the Ethics of Animal Experiments of the
Fondazione IRCCS Istituto Nazionale dei Tumori. All experi-
ments were designed to minimize the numbers of animals used and
their discomfort.
Tumor Samples and Cell Culture
The GB cell lines were established from fresh GBM surgical
specimens collected directly from the operating theatre in PBS plus
0,6% glucose and immediately transported on ice to the cell
culture room and processed and cultured as monolayer cultures as
previously described [29]. Briefly, fresh tumor samples or
xenografts were manually dissociated into single cells by enzymatic
digestion with Accutase (Sigma) for 15–20 min at 37uC. Tumor
cells suspension was then seeded into a fresh laminin-coated plastic
plate. GB cells and control foetal human Neural Stem cells (hNS
cells) were derived and grown in self renewal serum-free medium
(SFM) containing EGF and FGF-2 (20 ng/ml; Peprotech), as
previously described [29,43]. Culture vessels were coated with
5 mg/ml Laminin (Invitrogen) for 3 hr prior to use. The
phenotype of these cultures was confirmed by analysis of stem
cell markers expression, in vitro assays of self-renewal, differenti-
ation potential and in vivo tumor formation and propagation. In
our analysis were included also other GB lines (G166 and G179
cells) and GBM neurospheres (NSGBnR1) previously described in
other studies [29,44]. For differentiation, single-cell suspensions of
GB cells and normal hNS cells were seeded on Laminin-coated 48-
well plates at 1.2610
4 cells/well density in proliferation medium
and subjected to lentiviral transduction [29,43]. 24 hours after
infection, the cells were shifted in the same basal media deprived of
both EGF and FGF-2 (growth factor withdrawal condition) and
supplemented with a double amount of B27 supplement (4%) for
15 days. Half of the medium was replaced every 2–3 days along
the differentiation period. GB7 and GB8 cell lines have been
deposited in the cell repository at Biorep (Milan, Italy).
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Knockdown of REST was achieved by means of lentiviral
vector–mediated short hairpin RNA (shRNA) interference, using
validated commercial lentiviral particles for the NRSF sequence
(Santa Cruz Biotechnology), or through small interference RNA
(siRNA), by employing oligonucleotides targeting human REST
transcript sequence (Invitrogen). For the infection, lentiviral
particles were gently diluted (1:70) in proliferation medium
supplemented with 5 mg/ml polybrene. Sub-confluent cultures
Figure 5. REST controls SCP1 and PTPN12 phosphatases expression levels in human tumorigenic-competent GBM cells by
modulating miR-124 levels. (A) Quantitative RT-PCR analysis shows elevated miR-124 expression following REST knockdown in GB7 cells (shREST;
4 days post infection) compared to CTRL and NT shRNA control cultures. miR-124 expression level was normalized to RNU48 levels. Results are
relative to three independent experiments. Data are means 6 s.d. (B) Expression levels of miR-124 targets, SCP1 and PTPN12 phosphatases, in GB cells
are controlled by REST. Downregulation of REST induces a reduction of the protein levels of SCP1 and PTPN12 in GB7 cells. Cultures were transduced
with with non targeting (NT shRNA) and REST (shREST) shRNA, cultured for 4 days and analysed for expression of SCP1 and PTPN12 by western blot
assay. CTRL sample represents the non trasfected culture. Alpha Tubulin levels were used as loading control. Data are means 6 s.d. ns not significant,
*P,0.001.
doi:10.1371/journal.pone.0038486.g005
Figure 6. Schematic diagram illustrating one of the hypothetical regulatory mechanisms by which REST controls the cellular status
in REST-expressing human tumorigenic-competent GBM cells (left box) and how this is perturbed in REST-depleted (right box)
cells.
doi:10.1371/journal.pone.0038486.g006
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to classic compete medium. Knockdown efficiency was determined
by immunocytochemistry, real time PCR and Western Blot
analysis on GB infected cells. Control nontargeting shRNA (NT
shRNA) Lentiviral Particles and cop GFP Control Lentiviral
Particles (Santa Cruz Biotechnology) were used as controls. The
latters were also used to monitor the transduction efficiency in vitro
and in vivo. For REST- siRNA knockdown three different siRNAs,
directed against different portion of human REST transcript, were
characterized for their knockdown efficiency by real time PCR
analysis on GB cells transfected with each REST targeting siRNAs
or with universal negative scrambled controls (Invitrogen). The
most efficient siRNA was used for all further experiments.
Nucleofection technology (Amaxa, Lonza) was used to transfect
the cells. For each nucleofection 4–5610
6 cells and 100pmole of
siRNA were used following the protocol according to the
manufacturer’s instruction. 50pmole of pMAX plasmid were used
as control.
Cell Assays
For colorimetric MTT-based cell viability assay cells were
plated in triplicate into 24 well plate at a density of 2610
4 cells/
well in self-renewal medium. At each time point considered, cells
were exposed to 3-[4.5-dimethylthiazol-2-phenyl]-2.5-diphenyl-
tertrazolium bromide (1 mg/ml) for 1 hour at 37uC and formazan
release was quantified at 560 nm using a Microplate Reader
(Biotek). For Active Caspase 3 analysis, 4610
6 cells were
transfected with control and specific siRNA as indicated above
and after 24 hours 1.5610
4 of nucleofected cells were plated in
triplicate into 96 well plate in proliferation medium. Degree of
apoptosis was assayed using Caspase-GloH 3 Assay (Promega) on
a Veritas
TM Microplate Luminometer (Promega) according to the
manufacturer’s protocol. For Annexin V staining, we used the
Annexin V Apoptosis Detection Kit (BD Pharmingen
TM). Cells
were nucleofected with NT siRNA and specific anti REST siRNA
as indicated in the previous section and stained with Annexin V at
different time points post nucleofection. The cells stained with
Annexin V and relative controls were analyzed by cytofluorimetry
with at least 10,000 events/determination, using FACSCantoII
and DiVA software for acquisition and analysis (BD Pharmin-
gen
TM).
Mouse Xenograft Assay
Xenotransplantation experiments were performed on SCID
mice (6–8 weeks old; Charles River Laboratories) housed in
pathogen-free conditions. For s.c. inoculation SCID mice were
anesthetized with i.m. ketamine and xylazine and a suspension 1:1
of 0.5610
6 cells and Matrigel was injected bilaterally (200 ml/
injection). Mice were monitored until the appearance of a mass
and were sacrificed by CO2 asphyxiation when the tumors were in
the exponential phase of growth. The explanted tumors were
mechanically dissected into 2 mm fragments used for in vitro serial
cell lines derivation and immunohistochemistry analysis. For in vivo
REST knockdown analysis 10
7 cells/mouse of viable GB cells non
transfected and transfected with NT siRNA or the selected REST
targeting siRNA were transplanted (48 hours after transfection
procedure) into mice through s.c. injection following the same
protocol described above. At least three SCID mice, receiving
a bilateral s.c. cell inoculation for each experimental condition
were used. For lentiviral-mediated REST shRNA treatment, GB
cells were first s.c. injected to establish glioma xenografts as
described above and the same quantity of NT lentiviral particles or
REST targeting lentiviral particles were delivered to tumor sites
through intratumoral injection. A second virus injection was
performed one week after the first treatment. The lentiviral
injection dose was defined by delivery of cop GFP Control
Lentiviral Particles; 80 ml lentiviral particles in 300 ml PBS (i.e.
1.2–1.5610
6 viral infectious units was chosen as injection dose.
For intracranial graft, SCID mice were anesthetized with i.m.
ketamine and xylazine. Thereafter, animals received a stereotaxic
injection of 1.5 ml (10
5 cells/ml) of GB cells suspension in the left
corpus striatum. Animals were monitored for 6 months for disease
symptoms and were sacrificed when they showed weight loss or
any other sign of disease.
Statistical Analysis
Statistical significance was assayed using a Student’s unpaired t
test or one-way ANOVA analysis of variance using the GraphPad
Prism software. P,0.05 was considered statistically significant.
Supporting Information
Figure S1 REST expression is elevated in human
gliomas. (A) The median intensity of REST transcript expression
is increased in human glioma patient samples in REMBRANDT
(REpository for Molecular BRAin Neoplasia DaTa, National
Cancer Institute) in comparison to non tumor tissue. (B) REST
gene (4q12) deletion is associated with increased glioma patient
survival in REMBRANDT.
(PDF)
Figure S2 REST expression in non GBM human brain
tumors. (A) Grade I astrocytoma: positive nuclei are almost
absent; (B) Grade II oligodendroglioma: ischemic neurons with
intense nuclear staining; (C) Grade III oligodendroglioma: many
nuclei are positive; (D) Pilocytic astrocytoma: all the nuclei are
positive; (E) Positive nuclei in medulloblastoma with no neuronal
differentiation; (F) negative nuclei in medulloblastoma with
neuronal differentiation. DAB, 4006.
(PDF)
Figure S3 Antigenic and biological properties of GB
cells. (A) Representative live image of GB7 cells in self-renewal
conditions. (B) MTT cell viability assay on GB7 cells (OD%:
relative optic density). Curve is relative to 2610
4 cells/well seeded
on laminin-coated 24-Multiwell Plate. Curve points are shown as
mean 6 s.d. of three independent replicates. (C) GB7 cells show
an antigenic expression pattern comparable to adherent human
fetal neural stem cell markers (NSCs), with high expression of NSC
markers (Nestin, Sox2, Olig2, Vimentin) and negligible expression
of neuronal (b3-tubulin) or glial (GFAP) markers. (D) Orthotopi-
cally xenografted GB7 cells form tumors in SCID mice. Kaplan-
Meyer survival curve of SCID mice (n=5) transplanted in-
tracranially with GB7 cells (150,000 cells per injection).
(PDF)
Figure S4 Elevated REST expression levels are pre-
served in serial heterotopic GB7 cell-derived xenografts
and in serial GB7 cell lines. (A) Immunohistochemistry for
REST (Left) and Nestin (Right) in tumors derived from GB7 cells
serial heterotopic xenografts (representative images from second
serial xenografts). (B) GB cells can be stably re-derived following
serial heterotopic xenograft propagation. After four in vivo passages
GB cells maintain the same morphological and antigenic features
of the parental GB cell line. Left: Representative live images of
proliferating GB7 serial cell lines I (derived from first xenograft), II
(derived from first serial xenograft), III (derived from second serial
xenograft) and IV (derived from third serial xenograft). Right:
Antigenic characterization for neural progenitors markers (nestin
and Sox2) of GB7 serial cell lines I, II, III and IV. (C) Quantitative
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PLoS ONE | www.plosone.org 10 June 2012 | Volume 7 | Issue 6 | e38486Real Time PCR analysis showing REST expression in serial GB7
cell lines. In all serial GB7 cell lines REST expression is grossly
maintained (GB7 I and IV cells: P,0.001; GB7 II and III cells:
P,0.05) to levels similar to GB7 parental cells. REST expression
levels were normalized to GAPDH. Data are relative to three
independent experiments and are presented as means 6 s.d. (D)
REST immunofluorescent staining on serial GB7 cell lines.
Similarly the parental GB7 cells, all the serial GB7 cell lines
homogenously show a prominent REST nuclear immunoreactive
signal.
(PDF)
Figure S5 REST shRNA silencing efficiency in GB7 cells.
(A) Live phase contrast and fluorescence images of GB7 cells 72
hours after infection (infection time: 24 hours) with GFP-
expressing lentiviral particles to assess infection efficiency. At this
time point, a 77.5% 66.7 efficiency of infection was determined.
(B, C and D) GB7 cells infected with lentiviral particles carrying
anti-REST shRNA (shREST) show a strong reduction in REST
expression both at mRNA and protein levels as determined by (B)
quantitative Real Time PCR analysis (REST transcript level in
CTRL group is set as 100; NT shRNA: 91.4% 67.4; shREST:
27.3% 66.6, P,0.001), (C) Western blotting (a 88.9% reduction
od REST immunoreactive signal in shREST group with respect to
control groups is determined) and (D) immunofluorescent staining.
No effects are evident on REST levels following infection of GB7
cells with non-targeting control shRNA (NT shRNA: 91.3% 68.7,
P not significant) or control GFP-expressing (eGFP: 94.1% 65.7, P
not significant) lentiviral particles. CTRL group is represented by
mock infected cultures. The immunofluorescent staining in (D)
shows a marked reduction in nuclear REST immunoreactivity
with some degree of persistence of signal in small dots inside the
nucleus. Results shown are relative to three independent
experiments. Data are means 6 s.d.
(PDF)
Figure S6 REST silencing in human tumorigenic-com-
petent GBM cells is not permissive for self-renewal. GB7
cells 48 hours after infection (infection time: 24 hours) with non-
targeting control shRNA (NT shRNA) or control GFP-expressing
(eGFP) lentiviral particles or with lentiviral particles carrying
shRNA anti-REST (shREST) were exposed to puromycin
selection (lentiviral particles carry a puromycin selection cassette)
in order to remove the fraction of non-infected cells. CTRL group
is represented by mock-infected cultures. Pictures are relative to
the different experimental groups at 0, 4, 7 and 12 days of
puromycin selection. Cultures which integrate controls lentiviral
particles (NT shRNA and eGFP groups) readily expand in
puromycin selection; shREST cells, even surviving, never pro-
liferate and degenerate after two weeks of selection. Non-infected
cultures (CTRL) were readily killed by puromycin selection.
Results shown are representative of three independent experi-
ments.
(PDF)
Figure S7 REST knockdown in human tumorigenic-
competent GBM cells impairs sphere formation effi-
ciency and sphere size. (A) 24 hours after infection,
tumorigenic-competent GBM cells grown as neurosphere
(NSGBnR1 line) infected with non-targeting control shRNA (NT
shRNA) or with lentiviral particles carrying shRNA anti-REST
(shREST) were plated (10
4 cells per well in a 24 well plate). CTRL
group is represented by mock-infected cultures. 24 hours after
plating, cells were exposed to 1 mm/mL puromycin selection
(lentiviral particles carry a puromycin selection cassette) in order to
remove the fraction of non-infected cells (no puromycin selection
was performed on CTRL cells). Representative live image of cells
ten days after plating show that the shREST cells formed fewer
and smaller neurospheres in comparison to both CTRL and NT
shRNA groups. Results shown are relative to three independent
experiments. (B and C) 24 hours after infection, NSGBnR1
neurosphere cells infected with non-targeting control shRNA (NT
shRNA) or with lentiviral particles carrying shRNA anti-REST
(shREST) were plated (1 cells per well in a 96 well plate; three
plates for a total of 288 wells were plated per each experimental
group). CTRL group is represented by mock-infected cultures.
Differently from cultures shown in (A), cells were not exposed to
puromycin selection in order to avoid any possible interference
with single cell analysis. The presence of clonal sphere in each well
was determined in two weeks. Quantification shows reduced
sphere number (total number of spheres in CTRL group is set as
100; NT shRNA: 98.3% 614.8, P not significant; shREST: 14.0%
65.8 P,0.001) (B) and size (sphere diameter) (C) for shREST cells
with respect to control groups. Data are means 6 s.d. (n=3). ns
not significant, *P,0.001, **P,0.05.
(PDF)
Figure S8 REST knockdown triggers neuronal differen-
tiation and cell death programs in human tumorigenic-
competent GBM cells. (A) Representative live image of GB7
cells exposed to differentiating conditions for 7 and 14 days after
lentiviral REST shRNA knockdown (shREST) and relative
controls (CTRL: untreated; NT shRNA: non targeting shRNA).
REST knockdown produces drop of proliferation and dramatic
morphological changes, with appearance of a pronounced pro-
portion of flat and differentiated cells. (B) Immunofluorescent
analyses of control(s) and shREST GB7 cells in differentiation
contitions (14 days post lentiviral shRNA infection). The number
of cells immunopositive for neural progenitor (Nestin and Olig2)
and proliferation (P-HisH3) markers in shREST cultures is
strongly lessened with respect to controls (CTRL and NT shRNA
groups), with a parallel increase of neuronal differentiation (b3-
tubulin) and apoptosis (Activated Caspase 3) markers. The number
of GFAP expressing cells is reduced in shREST cultures with
respect to the control cultures, indicating that REST derepression
strongly favors the conversion toward the neuronal lineage at the
expenses of the glial lineage. (C) Relative quantification of the
numbers of immunoreactive cells in (B). CTRL: light gray bars;
NT shRNA: dark gray bars; shREST: black bars. At least 700 cells
per group were scored. Results shown are relative to three
independent experiments. Data are means 6 s.d. ns not significant,
*P,0.001, **P,0.05.
(PDF)
Figure S9 REST siRNA silencing efficiency in GB cells.
(A) Live fluorescent images of GB7 cells 48 hours after
nucleofection with three different anti REST siRNAs (siREST#1,
1, siREST#2, siREST#3) each directed against a distinct region
of REST transcript or with non targeting control siRNA (NT
siRNA) and co-transfected with a GFP-carrying plasmid (eGFP) to
assess nucleofection efficiency. The transfection efficiency and the
fluorescence levels on siREST cultures are comparable to control
cultures. Average nucleofection efficiency: 74.6% 68.3. (B) REST
siRNA targeting efficiently reduces REST transcript levels in GB
cells. Real Time PCR analysis showing REST expression in
siREST nucleofected GB7 cells and in control (CTRL, eGFP and
NT siRNA) cultures. REST expression level was normalized to
GAPDH. REST transcript level in CTRL group is considered as
100%. Best knockdown efficiency is achieved with siREST#1
(siREST#1: 17.3% 63.5, P,0.001; siREST#2: 29.7% 65.1,
P,0.001; siREST#3: 24.2% 64.4, P,0.001) which was selected
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nucleofection in NT siRNA (116.4615.6, P not significant) or
GFP (98.3617.1, P not significant) cultures. Data are relative of
three independent experiments and are presented as mean 6 s.d.
(C) REST knockdown de-represses the REST-mediated silencing
activity on target genes transcription in GB cells. Quantitative
Real Time PCR analysis of transcripts levels of REST-controlled
genes (BDNF and SNAP25) in siREST nucleofected (96 hours
after transfection) and control GB7 cultures. RNA was purified
from GB7 cells nucleofected with either anti-REST siRNA #1
(siREST#1) or non-targeting control siRNA (NT siRNA). RNA
extracted from mock nucleofected cells was used as control
(CTRL). GAPDH was used as housekeeping gene to normalize
REST expression levels. The mRNA expression levels of CTRL
group was set to 100 for each gene and data are shown as
percentage of CTRL. REST targeting leads to a marked de-
repression of REST-target genes (BDNF: 224.4% 617.2,
P,0.001; SNAP25: 526.9% 617.8, P,0.001). No effect on
expression levels of all the genes after transfection with NT siRNA
(BDNF: 77.8614.4, P.0.001; SNAP25: 74.6% 618.9, P.0.001).
Data are relative of three independent experiments and are
presented as means 6 s.d.
(PDF)
Figure S10 REST knockdown abolishes orthotopic xe-
nograft tumor formation by human tumorigenic-com-
petent GBM cells. GB7 cells transduced with NT shRNA or
shREST lentiviral particles were injected into brains of SCID mice
(150,000 cells per mouse; prior to transplantation, cultures were
puromycin-selected for three days in order to eliminate non-
infected cells). Four mice were injected for each group. Mice in the
control group were sacrificed upon the development of neurologic
signs. All the mice bearing shREST GB7 cells did not develop
neurologic signs and were sacrificed after 180 days without
evidence of tumor formation. (A and B) Representative images of
coronal sections of grafted brains. H&E staining demonstrated the
presence of brain tumors in mice injected with NT shRNA GB7
cells (A), while no tumors were observed in brains of mice injected
with shREST GB7 cells (B). Insets in (A and B) show whole
sections of the grafted brains. (C–F) Immunohistochemical
staining of brain sections from NT shRNA mice (C and E) and
shREST mice (D and F) with antibodies against nestin (C and D)
and PCNA (E and F).
(PDF)
Figure S11 In vivo intra-tumoral injection of REST
shRNA impairs growth of heterotopic established tu-
mors. (A) In vivo lentiviral injection of control GFP-expressing
lentiviral particles in established GB7 cells-derived xenograft
tumors in SCID mice. GB7 cells were subcutaneously implanted
into mice flanks and, once tumors were well established (42 days
after grafting), GFP-expressing lentiviral particles were delivered to
the tumor site through direct single injection in order to assess the
infection efficiency. One-week post virus injection mice were
sacrificed and tumor tissue sectioned. Representative fluorescent
images of tumor section show the presence of eGFP signal
indicative for the occurrence of a local infection of the tumor mass.
(B) Lentiviral particles carrying either non-targeting shRNA or
shRNA directed against REST were delivered to tumor site (42
days old GB7 cell-derived xenografts; n=4 for each group)
through direct injection (two injections with 7 days interval).
Fifteen days after the last virus injection, mice were sacrificed and
tumor tissue sectioned. H&E staining of tumor tissue sections
enlightens the presence of areas with reduced cellular density in
the shREST injected tumors, indicating focal infected areas where
possibly cell death has occurred. The tissue from NT shRNA
infected tumors shows a more uniform cellular density. Repre-
sentative immunohistochemical staining of tumor tissue sections
from NT shRNA and shREST groups with antibodies against b3-
tubulin and Active Caspase-3 show indeed the presence of
immunoreactive areas in shREST infected tumors.
(PDF)
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